Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA).
Frodlund M, Nived P, Chatzidionysiou K, Södergren A, Klingberg E, Hansson M, Ohlsson S, Pin E, Bengtsson A, Klareskog L, Kapetanovic M. Frodlund M, et al. Among authors: chatzidionysiou k. Microbiol Spectr. 2024 Apr 2;12(4):e0298123. doi: 10.1128/spectrum.02981-23. Epub 2024 Mar 5. Microbiol Spectr. 2024. PMID: 38441463 Free PMC article.
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.
Sundén-Cullberg J, Chen P, Häbel H, Skorup P, Janols H, Rasmuson J, Niward K, Östholm Balkhed Å, Chatzidionysiou K, Asgeirsson H, Blennow O, Parke Å, Svensson AK, Muvva JR, Ljunggren HG; Karolinska KI/K COVID-19 Treatment Working Group; Horne AC, Ådén U, Henter JI, Sönnerborg A, Vesterbacka J, Nowak P, Lampa J. Sundén-Cullberg J, et al. Among authors: chatzidionysiou k. PLoS One. 2023 Dec 29;18(12):e0295838. doi: 10.1371/journal.pone.0295838. eCollection 2023. PLoS One. 2023. PMID: 38157348 Free PMC article. Clinical Trial.
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden.
Bower H, Frisell T, di Giuseppe D, Delcoigne B, Lindström U, Turesson C, Chatzidionysiou K, Lindqvist E, Knight A, Forsblad-d'Elia H, Askling J. Bower H, et al. Among authors: chatzidionysiou k. RMD Open. 2023 Dec 26;9(4):e003648. doi: 10.1136/rmdopen-2023-003648. RMD Open. 2023. PMID: 38151264 Free PMC article.
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study.
van der Togt CJT, Van den Bemt B, Aletaha D, Alten R, Chatzidionysiou K, Galloway J, Isaac J, Mulleman D, Verschueren P, Vulto AG, Welsing PMJ, Verhoef L, den Broeder AA. van der Togt CJT, et al. Among authors: chatzidionysiou k. RMD Open. 2023 Mar;9(1):e002898. doi: 10.1136/rmdopen-2022-002898. RMD Open. 2023. PMID: 36863753 Free PMC article. Review.
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme.
Frisell T, Bower H, Morin M, Baecklund E, Di Giuseppe D, Delcoigne B, Feltelius N, Forsblad-d'Elia H, Lindqvist E, Lindström U, Askling J; ARTIS Study group. Frisell T, et al. Ann Rheum Dis. 2023 May;82(5):601-610. doi: 10.1136/ard-2022-223762. Epub 2023 Feb 14. Ann Rheum Dis. 2023. PMID: 36787994 Free PMC article.
81 results